Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 3,334 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Andrew Hollman Meyer also recently made the following trade(s):

• On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $54.88, for a total value of $731,769.92.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $39.37 on Friday. The firm has a market capitalization of $2.07 billion, a P/E ratio of -33.65 and a beta of 3.16. Janux Therapeutics, Inc. has a one year low of $7.81 and a one year high of $71.71. The business has a fifty day moving average price of $51.07 and a 200-day moving average price of $48.28.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s quarterly revenue was down 82.6% on a year-over-year basis. Sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

JANX has been the topic of a number of research analyst reports. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Stifel Nicolaus increased their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Scotiabank lifted their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. Leerink Partners increased their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Finally, Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Janux Therapeutics has an average rating of “Buy” and an average price target of $89.90.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Plato Investment Management Ltd grew its stake in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after acquiring an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics in the fourth quarter worth $139,000. Chicago Capital LLC bought a new position in shares of Janux Therapeutics in the fourth quarter worth $230,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Janux Therapeutics in the second quarter worth $215,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.